FDA, EMA to review Biogen Idec's Plegridy for MS

Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA and EMA accepted an MAA for Plegridy peginterferon beta-1a ( BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company...